Association of Cytidine Deaminase Polymorphism with Capecitabine Effectiveness in Breast Cancer Patients
- PMID: 38156857
- PMCID: PMC10909096
- DOI: 10.31557/APJCP.2023.24.12.4219
Association of Cytidine Deaminase Polymorphism with Capecitabine Effectiveness in Breast Cancer Patients
Abstract
Objective: Cancer is caused by abnormal growth and disruption of homeostatic mechanisms. Breast cancer is a major health problem and the second leading cause of death in women. Capecitabine is a prodrug of 5-fluorouracil, which is a non-cytotoxic agent and is used to treat advanced or metastatic breast cancer. Cytidine deaminase (CDA) plays an important role in the activation of capecitabine by acetylating 5-deoxycytidine in the liver, which ultimately leads to the formation of 5-fluorouracil. In this study, we aimed to investigate the relationship between cytidine deaminase polymorphism and capecitabine efficacy in breast cancer patients.
Methods: One hundred breast cancer patients aged 45 to 75 years were included in this study, all of whom received capecitabine as monotherapy. The serum levels of CA15.3, calcium, and estradiol E2 in breast cancer patients were investigated. In addition, the relationship of these markers with cytidine deaminase polymorphism was investigated in order to show the association of cytidine deaminase polymorphism with capecitabine efficacy in breast cancer patients.
Result: The findings of this study showed that there is a statistically significant relationship between CDA enzyme polymorphisms (rs2072671 and rs532545) with estradiol and CA15.3 serum levels and a non-significant relationship with calcium level. Furthermore, patients who participated were highly polymorphic and heterozygotes genotypes had the highest frequency in both rs2072671 and rs532545 polymorphisms.
Conclusion: The results obtained from the present study identified different genetic polymorphisms in the gene encoding the CDA enzyme. Overall, our results clearly showed direct evidence for the association of cytidine deaminase polymorphism with the efficacy of capecitabine in breast cancer patients, which could be useful in reducing side effects and improving drug response to capecitabine.
Keywords: Cytidine Deaminase; Polymorphism; breast cancer; capecitabine.
Conflict of interest statement
The authors declare that they have no conflict of interests.
Similar articles
-
Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.Pharmacol Res. 2018 Feb;128:122-129. doi: 10.1016/j.phrs.2017.08.005. Epub 2017 Aug 18. Pharmacol Res. 2018. PMID: 28827188 Clinical Trial.
-
The role of pharmacogenetics in capecitabine efficacy and toxicity.Cancer Treat Rev. 2016 Nov;50:9-22. doi: 10.1016/j.ctrv.2016.08.001. Epub 2016 Aug 10. Cancer Treat Rev. 2016. PMID: 27569869 Review.
-
Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.Gene. 2015 Mar 15;559(1):31-7. doi: 10.1016/j.gene.2015.01.010. Epub 2015 Jan 10. Gene. 2015. PMID: 25582275 Review.
-
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.Clin Cancer Res. 2011 Apr 1;17(7):2006-13. doi: 10.1158/1078-0432.CCR-10-1741. Epub 2011 Feb 16. Clin Cancer Res. 2011. PMID: 21325291
-
Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.Cancer Chemother Pharmacol. 2009 May;63(6):1177-80. doi: 10.1007/s00280-008-0889-1. Epub 2008 Dec 24. Cancer Chemother Pharmacol. 2009. PMID: 19107485
References
-
- Abbas YJ, Al-Tu’ma FJ, Al-Hemerri AF. Association between Matrix Metalloproteinas-2 Gene Variants and Pathogenesis of Breast Cancer in Sera of Iraqi Women. Contemp Med Sci. 2020;6:285–90.
-
- Abed SN, Mahdi HS, Sahib AS, et al. Serum levels of cancer antigen 15 3 and estrogen in a samples of iraqi women with breast cancer treated with anastrazole. Int J Pharm Res. 2020;12:1604–8.
-
- Al-Kelabi HM, Al-Tu’ma FJ, Al-Hasnawy TSM, Al-Tu’ma AF, Hussein AF. Association between 25 (OH) D3 and Estrogens in Iraqi Postmenopausal Osteoporotic Women with Type 2 Diabetes. HIV Nurs. 2022;22:638–43.